Telix Appoints David Gill as Non-Executive Director

Pharmaceutical company Telix names new board member with extensive industry experience.

Apr. 2, 2026 at 1:37am

Got story updates? Submit your updates here. ›

Telix Pharmaceuticals, a global biopharmaceutical company focused on the development of diagnostic and therapeutic products, has appointed David Gill as a new non-executive director to its board. Gill brings over 30 years of experience in the pharmaceutical and life sciences industries to Telix.

Why it matters

The addition of an experienced industry veteran like David Gill to Telix's board signals the company's commitment to strategic growth and expansion as it develops innovative diagnostic and therapeutic products. Gill's expertise will help guide Telix through key business decisions and regulatory milestones.

The details

In his new role, Gill will provide oversight and guidance to Telix's executive team as the company continues to advance its pipeline of radiopharmaceutical products. Gill previously served in senior leadership positions at several major pharmaceutical firms, including Eli Lilly and Roche.

  • Telix announced Gill's appointment on April 2, 2026.

The players

Telix Pharmaceuticals

A global biopharmaceutical company focused on the development of diagnostic and therapeutic products.

David Gill

An experienced pharmaceutical executive with over 30 years of industry experience, who has been appointed as a new non-executive director on Telix's board.

Got photos? Submit your photos here. ›

The takeaway

Telix's appointment of David Gill to its board demonstrates the company's commitment to strengthening its leadership and expertise as it works to bring innovative radiopharmaceutical products to market.